Yuhan (XKRX:000100) Common Stock : ₩80,209 Mil (As of Mar. 2024)

View and export this data going back to 1962. Start your Free Trial

What is Yuhan Common Stock?

Yuhan's quarterly common stock stayed the same from Sep. 2023 (₩76,639 Mil) to Dec. 2023 (₩76,639 Mil) but then increased from Dec. 2023 (₩76,639 Mil) to Mar. 2024 (₩80,209 Mil).

Yuhan's annual common stock increased from Dec. 2021 (₩69,973 Mil) to Dec. 2022 (₩73,231 Mil) and increased from Dec. 2022 (₩73,231 Mil) to Dec. 2023 (₩76,639 Mil).

Yuhan Common Stock Historical Data

The historical data trend for Yuhan's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yuhan Common Stock Chart

Yuhan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

63,885.58

66,856.81

69,972.96

73,231.48

76,638.66

Yuhan Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															76,638.66	76,638.66	76,638.66	76,638.66	80,209.06

Yuhan Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Yuhan (XKRX:000100) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yuhan Corp (XKRX:000100) » Definitions » Common Stock

Traded in Other Exchanges

000105:Korea

Address

74, Noryangjin-ro, Dongjak-gu, Seoul, KOR

Website

http://www.yuhan.co.kr

Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplement, household and animal care, and contract manufacturing of active pharmaceutical ingredients. Yuhan offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.

Yuhan (XKRX:000100) Headlines

No Headlines